In breast tissue, tamoxifen is an ER antagonist, but unfortunately, it is an ER agonist in uterine tissue, thereby promoting the proliferation of the endometrium and elevating the risk of uterine cancer. The gene discussed is ESR1; the disease is uterine cancer.